Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Lineage Cell Therapeutics, Inc. LCTX

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for...


Recent & Breaking News (NYSEAM:LCTX)

Lineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

Business Wire 5 hours ago

Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Business Wire 1 day ago

Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

Business Wire November 10, 2022

Lineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022

Business Wire November 3, 2022

Lineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer

Business Wire October 31, 2022

Lineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium Cells

Business Wire October 10, 2022

Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa

Business Wire October 4, 2022

Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel

Business Wire October 3, 2022

Lineage to Present at H.C. Wainwright & Co. 2nd Annual Virtual Ophthalmology Conference

Business Wire August 15, 2022

Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Business Wire August 11, 2022

Lineage Cell Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022

Business Wire August 4, 2022

Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology

Business Wire June 2, 2022

Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Business Wire May 12, 2022

Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022

Business Wire May 5, 2022

RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration

Business Wire May 3, 2022

Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022

Business Wire April 26, 2022

Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness

Business Wire April 25, 2022

Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer

Business Wire April 13, 2022

Lineage to Present at the NobleCon18 Investor Conference on April 20, 2022

Business Wire April 11, 2022

Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022

Business Wire March 24, 2022